Evaluation of efficacy and safety of active vitamin D treatment for secondary hyperparathyroidism in patients on maintenance hemodialysis; competitive study

INTERVENTION: affacalcidol maxacalcitol CONDITION: secondary hyperparathyroidism(SHPT) PRIMARY OUTCOME: The percentage achievement of recommendation value (60‐180pg/mL) of intact parathyroid hormone(PTH). INCLUSION CRITERIA: 1)Renal dysfunction: end‐stage chronic kidney disease, require maintenance dialysis due to renal dysfunction 2) Expected survival time is more than 6 months 3)Fully informed consent was obtained 4)Intact PTH level 180pg/mL‐500pg/mL 5)Serum P level 3.5‐7.0mg/dL 6)Serum adjusted Ca 8.4‐10.5mg/dL